Becton, Dickinson and Company announced a strategic collaboration with Ypsomed, a developer of injection systems, to advance self-injection solutions for high-viscosity biologic drugs. “In a joint project, Ypsomed and BD have pre-assessed and streamlined integration of the BD Neopak XtraFlow Glass Prefillable Syringe with Ypsomed’s YpsoMate 2.25 autoinjector platform, addressing current limitations by enabling the delivery of higher viscosity biologic drugs in an autoinjector format,” the companies stated. “Cross-supplier collaborations are vital in today’s pharmaceutical ecosystem,” said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. “These partnerships can help drive innovation and ensure that systems work by design and over lifecycles, allowing our pharmaceutical partners to get life-saving therapies to patients faster.”
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- ICU Medical initiated with a Hold at Jefferies
- Tela Bio’s OviTex ‘primary beneficiary’ of BD settlement, says Lake Street
- Becton hernia settlements cost over $1B, Bloomberg reports
- Becton Dickinson Settles Majority of Hernia Litigation
- Becton Dickinson in pact to to resolve vast majority of hernia litigation